好色先生

好色先生

Explore the latest content from across our publications

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Clinical Features of Patients with Acute Symptomatic Seizures in Ischemic Stroke and Risk for Post-stroke Epilepsy
Cerebrovascular Disease and Interventional Neurology
P9 - Poster Session 9 (5:00 PM-6:00 PM)
5-002

To characterize the clinical features associated with acute symptomatic seizures in acute ischemic stroke and identify risk factors for seizure recurrence.

Patients with acute symptomatic seizures in the setting of acute stroke have increased risk for post-stroke epilepsy, but most do not experience seizure recurrence. Identification of patients at higher risk for seizure recurrence could guide decision-making regarding need for long-term therapy which has potential detrimental effects on neurological recovery. 

We performed a retrospective review of patients admitted to our institution between 2019-2023 with acute ischemic stroke and acute symptomatic seizures, excluding patients with epilepsy and other pathologies associated with seizures. We registered data on seizure and stroke features and acute seizure risk factors during the hospitalization and post-hospital follow-up. Acute seizure risk factors included hyperglycemia (glucose > 300 mg/dL) on admission, benzodiazepine withdrawal, and electrolyte disturbances. Exploratory univariate analyses were performed to assess associations for seizure recurrence.

52 patients had acute symptomatic seizures. Average follow-up duration was 22.9 months (range 1-60 months). Seizures occurred on the day of stroke presentation in 40/52 (76.9%) patients and were recognized before the stroke in 32/52 (61.5%) patients. 16/52 (30.8%) patients had acute risk factors for seizures. EEG most frequently showed nonspecific slowing (29/52, 55.8%) and 6/52 (12.2%) had lateralized periodic discharges. Late seizures recurred in 15/52 (28.8%) patients. The presence of acute seizure risk factors was significantly associated with late seizure recurrence (Chi square p = 0.025).

Acute symptomatic seizures tend to occur in the hyperacute period in acute ischemic stroke and often precede stroke symptoms. Acute seizure risk factors were associated with increased risk for late seizure recurrence. Further data collection will be conducted to elucidate risk for individual clinical features and relate these to other findings that convey risk for epilepsy.

Authors/Disclosures
Madeline Russell, MD
PRESENTER
Dr. Russell has nothing to disclose.
Robin N. Dharia, MD Dr. Dharia has nothing to disclose.
Michael R. Sperling, MD, FAAN (Thomas Jefferson University) Dr. Sperling has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Neurelis. The institution of Dr. Sperling has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Medtronic. Dr. Sperling has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for UCB Pharma. Dr. Sperling has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Medscape. Dr. Sperling has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for International Medical Press. Dr. Sperling has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Projects for Knowledge. The institution of Dr. Sperling has received research support from SK Life Science. The institution of Dr. Sperling has received research support from UCB Pharma . The institution of Dr. Sperling has received research support from Takeda. The institution of Dr. Sperling has received research support from Neurelis. The institution of Dr. Sperling has received research support from Engage Therapeutics . The institution of Dr. Sperling has received research support from Medtronic. The institution of Dr. Sperling has received research support from Cavion. The institution of Dr. Sperling has received research support from Xenon Pharma. The institution of Dr. Sperling has received research support from Cerevel. The institution of Dr. Sperling has received research support from National Institutes of Health . The institution of Dr. Sperling has received research support from DARPA. Dr. Sperling has received publishing royalties from a publication relating to health care. Dr. Sperling has received publishing royalties from a publication relating to health care. Dr. Sperling has received personal compensation in the range of $500-$4,999 for serving as a Vice President with Epilepsy Consortium .